Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031
- Composition of matter patent to be granted in Europe on several products including AsiDNA™ as such until 2031, with potential extension to 2036
- Onxeo’s intellectual property for DNA-targeting technologies, products and combinations now protected by 10 patent families worldwide
Paris (France), January 25, 2018 – 8:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced having received a communication from the European Patent Office (EPO) informing the Company of its intent to grant a new patent covering AsiDNA™, Onxeo’s first-in-class DNA break repair inhibitor candidate in all countries of the European Union (EU).
This new patent significantly strengthens the Company’s intellectual property portfolio by protecting several conjugated nucleic acid molecules including AsiDNA™ as well as the pharmaceutical compositions and their therapeutic uses, especially for treating cancer, standalone and in combination with a DNA-damaging antitumoral agent (such as radiotherapy, chemotherapy or other tumor DNA damage-inducing agents).
This European patent has a term expiring in mid-2031. This term could be further extended to mid-2036 through a supplementary protection certificate (SPC).
The similar US patent was granted in July 2016.
“This patent covering the composition of matter provides the strongest protection possible in the field of Intellectual Property and is a key component of the value of AsiDNA™. This enlarged patent protection is key in a year when the company accelerates clinical development of AsiDNA™ to reach the next meaningful value inflexion points in the coming months,” said Judith Greciet, Chief Executive Officer of Onxeo.